🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Nimenrix powder and s

    Sanofi Pasteur

    Healthy volunteers (Meningococcal infection)

    phase 3 small molecule active

    1 trial

  2. Niraparib - capsule - 100 mg, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for ABIRATERONE ACETATE, -, Niraparib, PREDNISOLONE , ABIRATERONE , Placebo for Niraparib, Abiraterone acetate - tablet - 250 mg, Placebo for NIRAPARIB / ABIRATERONE ACETATE 50/500 mg FDC, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Prednison acis 5 mg, Tabletten, Placebo for NIRAPARIB / ABIRATERONE

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  3. Niraparib Placebo Capsules, Niraparib Placebo Tablets, G5W (5% glucose in water), JEMPERLI 500 mg concentrate for solution for infusion

    TESARO Bio Netherlands B.V.

    Recurrent or primary advanced (Stage III or IV) endometrial cancer

    phase 3 small molecule active

    1 trial

  4. Niraparib Placebo Tablets

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  5. Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  6. Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Capivasertib, NUBEQA 300 mg film-coated tablets, CABAZITAXEL, ENZALUTAMIDE , DAROLUTAMIDE , ABIRATERONE , ABIRATERONE ACETATE, APALUTAMIDE , RADIUM (223RA) DICHLORIDE , DOCETAXEL , OLAPARIB, Capivasertib, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, BAY 1841788

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  7. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Participants with completely resected Stage III or Stage IV melanoma

    phase 3 small molecule active

    1 trial

  8. Nivolumab Subcutaneous, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  9. Nomlabofusp, Placebo to Nomlabofusp

    Larimar Therapeutics

    Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.

    phase 3 small molecule active

    1 trial

  10. Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen

    NovoThirteen

    Children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature

    phase 3 small molecule active

    1 trial

  11. NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection, Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ADVATE 1 500 IU/2 ml powder and solvent for solution for injection, Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ELOCTA 500 IU Powder and solvent for solution for injection, ELOCTA 750 IU Powder and solvent for solution for injection, ELOCTA 2000 IU Powder and solvent for

    Hoffmann-La Roche

    Type 3 Von Willebrand Disease

    phase 3 small molecule active

    1 trial

  12. Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation, Sterile 0.9% (w/v) sodium chloride solution in single-use PFS

    GlaxoSmithKline

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  13. Nplate 500 micrograms powder for solution for injection, Placebo will be provided in identical 5 mL single-use vials as a sterile, white, preservative-free, lyophilized powder containing histidine, mannitol, sucrose, and polysorbate 20 and has a pH 5.0 when reconstituted with sterile water for injection., Nplate 500 micrograms powder for solution for injection

    Amgen

    Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

    phase 3 small molecule active

    1 trial

  14. Nucala 100 mg powder for solution for injection, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, SODIUM CHLORIDE, PLACEBO D AZATHIOPRINE

    Pari Pharma GmbH

    Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome

    phase 3 small molecule active

    1 trial

  15. OAV101

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 gene therapy completed

    1 trial

  16. OAV101B, Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  17. OBI-1

    Takeda

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  18. OBI-1

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  19. OBINUTUZUMAB, RITUXIMAB

    Pari Pharma GmbH

    Idiopathic nephrotic syndrome (INS)

    phase 3 small molecule active

    1 trial

  20. OCA 5MG IR +BZF 400 MG SR

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  21. OCA IR 0.1 mg, 0,1 mg and 1,5 mg Placebo tablets, OCA 1.5 mg

    Lacuna Pharma Pty Ltd

    Biliary Atresia, Post-hepatoportoenterostomy

    phase 3 small molecule active

    1 trial

  22. OCRELIZUMAB, LOU064, OCRELIZUMAB

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  23. OCTAGAM 10 %, Lösung zur intravenösen Infusion, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Prednisolone 5mg Tablets, Methotrexate 10 mg Tablets, Vinblastine Sulfate 1 mg/ml Solution for Injection or Infusion, Melphalan 50 mg Powder and Solvent for Solution for Injection/Infusion, INDOMETACIN CAPSULES BP 25mg, LEMTRADA 12 mg concentrate for solution for infusion, Mercaptopurine Silver Pharma 50 mg tablets, LITAK 2 mg

    The George Institute

    Langerhans Cell Histiocytosis

    phase 3 small molecule active

    1 trial

  24. OFOBA : Opioid-Free versus Opioid-Based Anaesthesia for free-flap reconstruction surgery of the breast: A phase III multicentric randomized controlled study.

    The George Institute

    Anaesthesia during free flap reconstruction surgery of the breast.

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources